Previous 10 | Next 10 |
Recro Pharma (NASDAQ: REPH ): Q1 GAAP EPS of -$0.10. More news on: Recro Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
MALVERN, Philadelphia, May 10, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a pharma company with a high-performing, revenue generating contract development and manufacturing (CDMO) segment and an Acute Care segment, today reported financial results for the three months ended ...
MALVERN, Pa., May 06, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH) today announced that it will report first quarter financial results on Friday, May 10, 2019. Recro's management team will host a conference call and audio webcast at 8:00 a.m. ET on Friday, M...
The following segment was excerpted from this fund letter published by Laughing Water Capital . In the 1H'18 letter, we introduced Avid Bioservices (CDMO) to the partnership. At one time, Avid had been working on commercializing pharmaceuticals, but its core business is that of a co...
Recro Pharma's (NASDAQ: REPH ) CDMO division, Recro Gainesville LLC has amended its existing license and supply agreement with Teva Pharmaceutical (NYSE: TEVA ) to extend the agreement for six years, effective January 1, 2019. More news on: Recro Pharma, Inc., Teva Pharmaceutical Industr...
Company Continues Important, Strategic Relationship with Key Global Customer; Long-Term Contract Executed Teva to Continue to be Exclusive Marketing Partner of Verapamil SR ® Capsules with Same Revenue Economics as the Original Agreement MALVERN, Pa., April 16, 2019 (GLOBE ...
New Meta-Analysis Data Suggests IV Meloxicam Produces Largest SPID, Greater Reduction in Opioid Use and Better Safety Profile Compared to Other Non-Opioid Medications for Moderate to Severe Pain Abstract Among the Highest Scoring Presentations at the Meeting MALVERN, Pa., April 11,...
On April 3rd, Recro Pharma (REPH) publicized its decision to cut operating expenses at its Acute Care Segment by reducing employee headcount by 50. This is in reaction to the company receiving its second CRL from the FDA concerning its IV Meloxicam candidate. This strategy intends to decre...
News, Short Squeeze, Breakout and More Instantly...
Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATE...
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing through Process Development and cGMP Manufacturing to Fill/Finish GAINESVILLE, Ga. ...
Recorded Q3 Revenue of $23.6 Million Signed Multiple New Business Agreements with New and Existing Customers Closed Public Offering Raising Gross Proceeds of Approximately $8.3 Million Initiated Corporate Restructuring; Expected to Result in Annualized Savings of Approxi...